295 reports of suspected side effects of implants in 2023 In 2023, 295 individuals reported one or more suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI).
RIVM European Reference Lab for vector-borne infections The European Commission (EC) has designated RIVM as the current European Reference Lab (EURL) for vector-borne viral pathogens.
Menno de Jong appointed director of RIVM Centre for Infectious Disease Control Starting 1 May 2024, Professor Menno de Jong will take on the role of director of RIVM’s Centre for Infectious Disease Control (CIb) . He succeeds Jaap van Dissel, who is retiring in April 2024.
Breast implants can cause health problems even five years or more after placement Over the past 5 years, the Dutch reporting and expertise centre for adverse effects of medical implants (MEBI) has received 977 reports of health problems related to breast implants. An analysis by RIVM has shown that 39% of the reported health problems started 5 or more years after the implant’s placement.
MEBI: 193 reports of suspected side effects of implants in 2022 In 2022, 193 individuals reported suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI). Most reports received concerned breast implants, copper IUDs and wrinkle fillers. This is highlighted in MEBI’s annual report.
No indication that investigated mesh implants used to treat pelvic organ prolapse are unsafe RIVM has conducted a laboratory study into six mesh implants from different manufacturers used in the Netherlands in 2018. The study revealed no indication that these products are unsafe for patients.
Urgent need for more research into environmental effects of microplastics Additional solutions are urgently needed to limit emissions of microplastics into the environment. Growing quantities of microplastics (particles of 5 mm or less) are entering our living environment every day.
More than two million invitations to get vaccinated against HPV in 2023 In early 2023, 1.3 million young adults will receive an invitation to get vaccinated against the human papillomavirus (HPV). This group comprises around 900,000 men and 400,000 women between the ages of 19 and 27.
Hypersensitivity reactions to fillers may occur after COVID-19 vaccination People may experience hypersensitivity reactions to fillers following a COVID-19 vaccination.
Current knowledge on microplastics in the soil is still inadequate A literature review carried out by the National Institute for Public Health and the Environment (RIVM) has concluded that reliable standard techniques should be developed to analyse microplastics in the soil.